WARRENDALE, Pa., May 19, 2011 /PRNewswire/ — MEDRAD, INC., a
business of Bayer HealthCare, has announced the launch of the next
generation Intego™ PET Infusion System, which features a new
design that is 38% smaller, power-driven and includes enhancements
to technologist workflow. The new Intego will be on display
at the Annual Meeting of the Society of Nuclear Medicine (SNM),
June 4-8, in San Antonio, Texas.
(Logo:
http://photos.prnewswire.com/prnh/20040309/MEDRADLOGO)
The Intego PET Infusion System, originally launched in 2008,
remains the only FDA-cleared device for automated, controlled
infusion of F18-FDG and F18-NaF, the most common PET diagnostic
imaging agents used in oncology. Intego PET Infusion Systems
have been sold throughout the world, including the US, Latin
America, South America, Europe, Africa, the Middle East, Asia and
Australia.
“The new Intego demonstrates our commitment to continued
innovation and leadership in molecular imaging. Now, in an
even smaller, more mobile design, Intego can significantly reduce
radiation exposure and improve patient care. This is just another
way we are driving smarter, safer, simpler PET,” says Doug
Descalzi, executive director, MEDRAD Molecular Imaging.
About MEDRAD, INC.
MEDRAD, INC. develops, markets and services medical devices used
to diagnose and treat disease. Its product offerings include fluid
injection systems for radiology and cardiology, endovascular
devices for the safe treatment of cardiovascular disease, magnetic
resonance-compatible accessories and equipment services. MEDRAD is
a two-time recipient of the Malcolm Baldrige National Quality
Award, the top honor a U.S. company can receive for quality and
business excellence (2003 and 2010). The company’s world
headquarters is near Pittsburgh, Pennsylvania, in the United
States. MEDRAD is a business of Bayer HealthCare. More company
information is available at
‘/>”/>
